Pemigatinib: NCCN Guidelines - Episode 5

Dr Al B. Benson Discusses Ongoing Work That Could Affect Future NCCN Guidelines

March 30, 2021

Al B. Benson, MD, FACP, FASCO, professor of medicine and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.

Al B. Benson, MD, FACP, FASCO, chair of the National Comprehensive Cancer Network (NCCN) hepatobiliary cancer guidelines panel, professor of medicine, and director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center, discusses hepatobiliary cancer research that may affect future NCCN guidelines.

Transcript

As you look ahead, what ongoing research do you anticipate will affect the next round of guideline updates?

I think in terms of the work that's ongoing, certainly there's more work looking at subtypes of patients. There are subgroups of patients, for example, with cholangiocarcinoma, including now, the BRAF population, patients with HER2-positive tumors and their ongoing trials. So, I think the identification further subsets, looking at combinations with immunotherapy—whether these are combinations with other immunotherapeutic drugs with, for example, TKIs, or chemotherapy combinations. These are all ideas that are under investigation currently.